Oculis (NASDAQ:OCS) Sets New 52-Week Low - What's Next?

Key Points

• Oculis shares fell 3.7% to a new 52-week low of $8.30, well below their 50-day moving average of $11.23 and 200-day moving average of $17.08.
• Analyst sentiment remains broadly positive, with nine Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $39.44. However, JPMorgan recently cut its target to $20, while HC Wainwright raised its target to $39.
• The biopharmaceutical company continues to report losses, including a quarterly EPS loss of $0.20 and a projected full-year loss of $2.01 per share. Institutional investors own 22.3% of the stock, and Oculis is developing ophthalmic treatments including OCS-01 and licaminlimab.

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) hit a new 52-week low during mid-day trading on Friday. The company traded as low as $8.30 and last traded at $8.34, with a volume of 161,880 shares changing hands. The stock had previously closed at $8.66.

Analyst Ratings Changes

OCS has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reduced their price target on Oculis from $23.00 to $20.00 and set an "overweight" rating for the company in a report on Friday, August 14th. HC Wainwright upped their price objective on Oculis from $26.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, September 18th. Wall Street Zen raised Oculis from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Oculis in a research note on Friday, July 17th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $39.44.

Oculis Trading Down 3.7%

The company has a market cap of $483.55 million, a P/E ratio of -4.79 and a beta of 0.62. The business has a fifty day moving average price of $11.23 and a 200-day moving average price of $17.08. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The firm had revenue of $0.38 million for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. On average, analysts forecast that Oculis Holding AG will post -2.01 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its stake in Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company's stock worth $1,855,000 after purchasing an additional 5,813 shares in the last quarter. Koshinski Asset Management Inc. acquired a new position in shares of Oculis during the 1st quarter worth approximately $238,000. Himension Capital Singapore PTE. LTD. acquired a new position in shares of Oculis during the 1st quarter worth approximately $503,000. Y Intercept Hong Kong Ltd bought a new position in shares of Oculis during the first quarter worth approximately $776,000. Finally, Squarepoint Ops LLC raised its position in shares of Oculis by 326.4% in the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company's stock valued at $854,000 after buying an additional 47,158 shares in the last quarter. Institutional investors and hedge funds own 22.30% of the company's stock.

About Oculis

Oculis NASDAQ: OCS is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis' pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.